|1.||Preffer, Frederic: 3 articles (02/2005 - 05/2003)|
|2.||Sykes, Megan: 3 articles (02/2005 - 05/2003)|
|3.||Spitzer, Thomas R: 3 articles (02/2005 - 05/2003)|
|4.||Shaffer, Juanita: 3 articles (02/2005 - 05/2003)|
|5.||Dey, Bimalangshu R: 2 articles (02/2005 - 05/2003)|
|6.||Colby, Christine: 2 articles (02/2005 - 05/2003)|
|7.||McAfee, Steven: 2 articles (02/2005 - 10/2003)|
|8.||Alexander, Stephen I: 2 articles (10/2003 - 05/2003)|
|9.||Saidman, Susan: 1 article (02/2005)|
|10.||Sachs, David: 1 article (02/2005)|
|1.||Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
07/01/2003 - "Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507."
07/01/2003 - "We evaluated the efficacy of MEDI-507 (a humanized monoclonal antibody directed against CD2) alone and in combination with humanized anti-Tac (HAT) directed toward CD25, the interleukin-2 receptor alpha (IL-2Ralpha) using a human adult T-cell leukemia xenograft model. "
|4.||Graft vs Host Disease (Graft-Versus-Host Disease)
10/01/2003 - "We have developed a nonmyeloablative approach to haploidentical HCT involving recipient treatment with a T cell-depleting mAb, Medi-507, that can achieve donor engraftment and mixed hematopoietic chimerism without graft-vs-host disease (GVHD). "
02/01/2005 - "Preparative therapy consisted of cyclophosphamide, equine anti-thymocyte globulin (ATG) or MEDI-507 (an anti-CD2 monoclonal antibody) for in-vivo T-cell depletion, thymic irradiation on day -1 and cyclosporine alone for graft-versus-host disease (GVHD) prophylaxis. "
|5.||Hematologic Neoplasms (Hematological Malignancy)
|1.||Interleukin-2 Receptor alpha Subunit
|4.||Antilymphocyte Serum (Anti-Thymocyte Globulin)
|1.||Heterologous Transplantation (Xenotransplantation)